Comparison between different lines of antiviral combination therapies against hepatitis c virus genotype 4 in egyptian patients
Mahmoud, Osman; Kadrey, Elsaeid; Neveen, Mosa; Shereen, Saleh; Khaled, Mansouer; Mohammed, Zaky.
Egyptian Journal of Hospital Medicine [The]. 2018; 72 (9): 5326-5333
en Inglés
| IMEMR | ID: emr-199996
Background:
hepatitis C virus [HCV] infection in one of worldwide chief causes chronic liver illness. The extended effect of it is highly inconstant, ranging from least histological changes to broad fibrosis and cirrhosis with possibility of hepatocellular carcinoma [HCC]. The morbidity and mortality of this global infection are growing. The estimated worldwide prevalence of HCV is a by the World Health Organization [WHO] affecting >170 million people worldwide. There is a varied distribution of HCV infection with about 23 million people likely to have it in the countries of Eastern Mediterranean Region. This is nearly number of infected people in both Americas and Europe. Egypt is considered to have highest prevalence worldwide with an expected 14.7% of total population seropositive for HCV
Biblioteca responsable:
EMRO
Documentos relacionados